Reading and driving in patients with normal baseline BCVA (20/25 or better in ≥1 eye) who received BVd in DREAMM-7 and BPd in DREAMM-8. Post hoc pooled analysis (BVd and BPd) of reading (A) and driving (B) in patients who had BCVA of 20/25 or better in ≥1 eye at baseline by time intervals since the first belamaf dose. (C) Summary of patients who stopped reading and driving. ∗Patients who could read with little or no difficulty or read with some difficulty at baseline, mainly due to eyesight issues, were considered, whereas those who stopped reading due to other reasons during follow-up were excluded. ^†The first 2.5 years of treatment are shown due to the limited number of patients at risk beyond this time point. ^‡Patients who could drive with little or no difficulty or drive with some difficulty at baseline, mainly due to eyesight issues, were considered, whereas those who stopped driving due to other reasons during follow-up were excluded. ^§Occurrences before the treatment end date are considered. ^||Time not being able to read/drive is the sum of days from when the patient stopped reading/driving to reading/driving with no, little, or some difficulty or the end of belamaf treatment, whichever is earlier, divided by the duration of belamaf treatment. EOT, end of treatment; IQR, interquartile range.